Venturing into New Waters: from researcher to entrepreneur
We are delighted to invite you to a special edition of the DCVA & RegMed XB Valorization Community event: “Venturing into New Waters – The
Innovate healthcare by fast-tracking your journey from idea to a fully funded, impactful venture
Impact officers transform promising ideas into investor-ready ventures. For more details, explore the following information and guidance. Our support is fully subsidized through the RVO TTT program.
DCVA and RegMed XB focus on patient-centric innovation, offering insights and funding.
We champion innovative science for chronic diseases. Discover our DCVA and RegMed XB projects.
At TTTransfer, we recognize the value of innovative startups and are committed to their growth. Our vouchers are designed to provide the financial boost you need.
Gain access to our network of key opinion leaders, investors and companies. We actively support you with getting in touch with the right people.
Experimental Voucher (€25k): Dive into research, testing, and validation. Turn your innovative ideas into actionable solutions.
Business Voucher (€25k): Refine your business strategy, optimize operations, and set the stage for success.
With our guidance, position your venture to attract and impress potential investors.
Access our exclusive funding pool designed to support startups in their early stages, ensuring they have the resources to thrive.
Impact officers transform promising ideas into investor-ready ventures. For more details, explore the following information and guidance.
We are delighted to invite you to a special edition of the DCVA & RegMed XB Valorization Community event: “Venturing into New Waters – The
📅 May 21st, 2024, from 3:00 PM to 6:00 PM (incl. drinks) 📍 Loyens & Loeff in Amsterdam This event is for: 🔬 Academic researchers in life sciences and
July 5, 2023 in F1RST Portfolio News • New Investor Libertatis Ergo Holding joins the financing round alongside existing investors FIRST Fund, KIKK Capital and Oost NL•
May 9, 2023 in F1RST Portfolio News 08 May 2023, Naarden, The Netherlands – Phlox Therapeutics (“Phlox”), a private biotechnology company specializing in developing innovative RNA-therapeutics for rare
In 2022, Dr. Bart Spee and Dr. Kerstin Schneeberger were awarded a RegMed XB Thematic Transfer Voucher, facilitating market analysis for their innovative bioreactor technology, the RPMotion.
Copyright © 2023 · TTTransfer · Design by Siracle Creatives